GMO Trust has recently filed a supplement to its prospectus, which includes significant updates regarding shareholder fees for its GMO Emerging Country Debt Fund and GMO Emerging Country Debt Shares Fund. This filing, dated November 4, 2026, is crucial as it outlines changes that could affect the costs associated with investing in these funds.

GMO Trust, based in Boston, Massachusetts, is an investment entity that focuses on asset management, particularly in emerging markets. The company has a history of providing investment products that cater to a diverse range of investors. This recent filing is part of their ongoing commitment to transparency and regulatory compliance.

The filing indicates that the sections on shareholder fees and examples in the prospectus have been entirely replaced. Specifically, the updated fee structure includes a purchase premium of 0.50% for Class III, Class IV, and Class VI shares, as well as a redemption fee of 0.50% for the same classes. Notably, the GMO Emerging Country Debt Shares Fund has a purchase premium of 0.00% for Class R6 shares, but a redemption fee of 0.50% applies.

This update is likely to impact current and prospective investors in these funds, as the revised fees may influence their investment decisions and overall costs. Investors will need to consider these adjustments when evaluating the potential returns from their investments in these funds.

Looking ahead, the filing does not specify what actions will follow these updates, such as additional filings or shareholder votes. Investors and industry observers will need to stay tuned for any further developments from GMO Trust regarding these changes.